When was Belharra founded?

Belharra was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Belharra located?

Belharra is headquartered in San Diego, United States.

How many employees does Belharra have?

As of May 31, 2026, the latest employee count at Belharra is 38.

Is Belharra a funded company?

Belharra is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jan 04, 2023.

When was the latest funding round of Belharra?

Belharra's latest funding was a $***** Series A round on Jan 04, 2023, with participation from 1 investor.

Where does Belharra rank among its competitors?

Belharra ranks 234th amongst 448 active competitors, of which 178 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Nimbus Therapeutics, which secured $210M in Sep, 2023.

Who are the top competitors of Belharra?

Belharra's top competitors include BioNTech, ADMA Biologics and Nimbus Therapeutics. Among them, Nimbus Therapeutics secured the most recent funding round in September, 2023.

Belharra - 2026 Company Profile, Team, Funding & Competitors

Belharra is a series A company based in San Diego (United States), founded in 2021. It operates as a Provider of photoaffinity-based chemoproteomics platform  for drug discovery. Belharra has raised $50M in funding. The company has 448 active competitors, including 178 funded and 108 that have exited. Its top competitors include companies like BioNTech, ADMA Biologics and Nimbus Therapeutics.

Company Details

Provider of photoaffinity-based chemoproteomics platform  for drug discovery. It offers an integrated chemoproteomic-based drug discovery engine to explore protein-ligand interactions in the cell. It is developing drugs for oncology, immuno-oncology, autoimmune and neurodegenerative diseases.

Website: belharratx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2021

Location

San Diego, United States

Stage

Series A

Total Funding

$50M in 1 round

Latest Funding Round

Series A, Jan 04, 2023, $*****

Investors

Versant Ventures

Ranked

234^th among 448 active competitors

Employee Count

38 as on May 31, 2026

Similar Companies

BioNTech & 523 more

View Belharra's full profile

Belharra has raised a total funding of $50M over 1 round. Its latest funding round was a Series A round on Jan 04, 2023 for $*****. 1 investor participated in its latest round. Belharra has 1 institutional investor.

Here is the list of recent funding rounds of Belharra:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 04, 2023	1209624	Series A	6230101	6264468	1329363	3679782

Access funding benchmarks and valuations. Sign up today!

View details of Belharra's funding rounds and investors

Belharra's employee count trend

Belharra has 38 employees as of May 26. Here is Belharra's employee count trend over the years:

Uncover Belharra's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Belharra include BioNTech, ADMA Biologics and Nimbus Therapeutics. Here is the list of Top 10 competitors of Belharra, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Redmile Group, Fidelity Investments & 28 others	72/100
2nd	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	71/100
3rd	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
4th	Apellis Pharmaceuticals 2008, Crestwood (United States), Public	Developer of therapeutics for the treatment of rare diseases	$213M	Sectoral, Hillhouse & 21 others	68/100
5th	PureTech Health 2001, Boston (United States), Public	Developer of immunotherapeutics for multiple diseases	$107M	Vitruvian Partners, Invesco Perpetual	67/100
6th	Cabaletta Bio 2017, Radnor (United States), Public	Developer of CAAR T cells for B cell-mediated autoimmune diseases	$88.3M	Boxer Capital, Deerfield & 5 others	67/100
7th	Vera Therapeutics 2016, San Francisco (United States), Public	Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases	$197M	Abingworth, Citadel & 13 others	66/100
8th	Astria 2008, Boston (United States), Acquired	Developer of therapeutics for rare diseases	$117M	MedImmune Ventures, Perceptive Advisors & 3 others	65/100
9th	Vividion Therapeutics 2016, Oceanside (United States), Acquired	Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers	$271M	Boxer Capital, Logos & 20 others	65/100
10th	Apogee Therapeutics 2022, Waltham (United States), Public	Developer of therapeutics for immunological and inflammatory disorders	$149M	Deep Track Capital, RTW Investments & 5 others	65/100
234th	Belharra 2021, San Diego (United States), Series A	Provider of photoaffinity-based chemoproteomics platform  for drug discovery	$50M	Versant Ventures	35/100